Volastra Therapeutics

Volastra Therapeutics, Inc., is in the process of creating new treatments for cancer. Originating from the research conducted by Dr. Lewis Cantley, in collaboration with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has uncovered the ways in which CIN contributes to the development and spread of solid tumors. After initial indications that a patient's CIN status is predictive and that CIN affects cellular and immune response mechanisms, resulting in poorer overall survival rates in animal models, the company is investigating the pathways through which CIN influences disease progression in order to develop innovative therapies.